Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
2.
Z Orthop Unfall ; 149(5): 541-5, 2011 Oct.
Article in German | MEDLINE | ID: mdl-21984424

ABSTRACT

BACKGROUND: Cranial magnetic resonance imaging (MRI) was performed in 250 patients who had been unconscious post-trauma for at least 24 hours. The frequency and the characteristics of injuries to the upper cervical myelon were determined. PATIENTS AND METHODS: Between 1996 and 2009, MRI was carried out within 8 days of trauma. RESULTS: No lesions of the upper cervical medulla were found without accompanying damage to the medulla oblongata. Two groups were found to have a lesion in the upper cervical myelon. (i) In 3.2 % of the patients in a state of deep coma MRI revealed lesions in the entire brain stem. These died without waking from coma. (ii) 2 % of the patients were found to have additional damage to the distal medulla oblongata. These victims of high-speed traumas awoke from coma after 2-3 days. They revealed frontal contusions of the brain and traumatic subarachnoidal hemorrhages. Injuries to the bony upper cervical spine and/or the skull base were frequent. Four of them died, one patient survived with severe disabilities. CONCLUSION: Two types of lesions involving the upper cervical myelon could be differentiated, both of which occur only in association with lesions in the medulla oblongata.


Subject(s)
Brain Injuries/diagnosis , Brain Stem/injuries , Medulla Oblongata/injuries , Spinal Cord Injuries/diagnosis , Adolescent , Adult , Aged , Aged, 80 and over , Brain Death/diagnosis , Brain Death/pathology , Brain Injuries/mortality , Brain Injuries/pathology , Brain Injuries/surgery , Brain Stem/pathology , Brain Stem/surgery , Cervical Vertebrae/injuries , Cervical Vertebrae/pathology , Cervical Vertebrae/surgery , Child , Child, Preschool , Female , Humans , Image Processing, Computer-Assisted , Infant , Magnetic Resonance Imaging , Male , Medulla Oblongata/pathology , Medulla Oblongata/surgery , Middle Aged , Prognosis , Quadriplegia/diagnosis , Quadriplegia/pathology , Quadriplegia/surgery , Skull Base/injuries , Skull Base/pathology , Skull Base/surgery , Spinal Cord Injuries/mortality , Spinal Cord Injuries/surgery , Subarachnoid Hemorrhage, Traumatic/diagnosis , Subarachnoid Hemorrhage, Traumatic/mortality , Subarachnoid Hemorrhage, Traumatic/pathology , Subarachnoid Hemorrhage, Traumatic/surgery , Survival Rate , Tomography, X-Ray Computed , Young Adult
3.
Nuklearmedizin ; 47(4): 147-52, 2008.
Article in English | MEDLINE | ID: mdl-18690373

ABSTRACT

AIM: [(18)F]fluoro-deoxyglucose positron-emission-tomography (FDG-PET) detects metabolic activity in alveolar echinococcosis (AE). The slow changes in metabolic and morphological characteristics require long-term follow-up of patients. This is the first study to evaluate metabolic activity over may years, hereby assessing the utility of FDG-PET for the evaluation of disease progression and response to treatment. PATIENTS, METHODS: 15 patients received a follow-up FDG-PET combined with computed tomography (integrated PET/CT) with a median of 6.5 years after the first PET in 1999. Number and location of enhanced metabolic activity in the area of AE lesions was determined. Quantification of intensity of metabolic activity was assessed by calculation of mean standardized uptake values. RESULTS: AE lesions in 11/15 patients had been metabolically inactive initially, but only two showed permanent inactivity over the course of 81 months. Interestingly, in two patients metabolic activity was newly detected after 80 and 82 months. Benzimidazole treatment was intermittently discontinued in seven cases. Persisting activity at FDG-PET demanded continued benzimidazole treatment in four patients. Neither treatment duration, lesional size, calcifications nor regressive changes correlated with metabolic activity. CONCLUSION: Treatment responses are heterogeneous and vary from progressive disease despite treatment to long-term inactive disease with discontinued treatment. Lack of metabolic activity indicates suppressed parasite activity and is not equivalent to parasite death. However, metabolic activity may remain suppressed for years, allowing for temporary treatment discontinuation. Relapses are reliably detected with PET and restarting benzimidazole treatment prevents parasite expansion.


Subject(s)
Echinococcosis, Pulmonary/diagnostic imaging , Echinococcosis, Pulmonary/metabolism , Fluorodeoxyglucose F18/pharmacokinetics , Follow-Up Studies , Humans , Image Processing, Computer-Assisted , Positron-Emission Tomography , Radiopharmaceuticals/pharmacokinetics , Time Factors , Tomography, X-Ray Computed , Treatment Outcome
4.
HNO ; 56(6): 627-32, 2008 Jun.
Article in German | MEDLINE | ID: mdl-18066514

ABSTRACT

Malignant melanomas (MMs) of the parotid gland are relatively uncommon. They occur almost invariably as metastases from a primary tumour located in the region of the scalp or the mucous membranes of the nose, paranasal sinuses, or throat. Primary MMs arising in the parotid gland are extremely rare. It is assumed that they originate in the glandular tissue or in intraglandular lymph nodes. We present a case report and review of the literature on the diagnosis, treatment, and prognosis of intraparotid malignant melanoma. Diagnosis is based primarily on B-scan ultrasonography and fine-needle aspiration cytology. Patients with a cytological diagnosis of MM are further evaluated by magnetic resonance imaging and positron emission tomography and receive a thorough ear-nose-throat and dermatological examination. The treatment of choice is total parotidectomy and selective neck dissection. The effectiveness of adjuvant treatments such as radiotherapy, chemotherapy, or immunotherapy remains controversial. Patients with primary MMs of the parotid gland appear to have a better prognosis than those with parotid metastases from melanomas of the skin or mucous membranes.


Subject(s)
Melanoma/diagnosis , Melanoma/therapy , Parotid Neoplasms/diagnosis , Parotid Neoplasms/therapy , Humans , Male , Middle Aged , Treatment Outcome
5.
Nuklearmedizin ; 46(1): 9-14; quiz N1-2, 2007.
Article in English | MEDLINE | ID: mdl-17299649

ABSTRACT

AIM: In this prospective study, reliability of integrated (18)F-FDG PET/CT for staging of NSCLC was evaluated and compared to MDCT or PET alone. PATIENTS, METHODS: 240 patients (pts) with suspected NSCLC were examined using PET/CT. Of those patients 112 underwent surgery comprising 80 patients with NSCLC (T1 n = 26, T2 n = 37, T3 n = 11, T4 n = 6). Imaging modalities were evaluated independently. RESULTS: MDCT, PET and PET/CT diagnosed the correct T-stage in 40/80 pts (50%; CI: 0.39-0.61), 40/80 pts (50%; CI: 0.39-0.61) and 51/80 pts (64%; CI: 0.52-0.74), respectively, whereas equivocal T-stage was found in 15/80 pts (19%; CI: 0.11-0.19), 12/80 pts (15%; CI: 0.08-0.25) and 4/80 pts (5%; CI: 0.01-0.12), respectively. With PET/CT, T-stage was more frequently correct compared to MDCT (p = 0.003) or PET (p = 0.019). Pooling stages T1/T2, T-stage was correctly diagnosed with MDCT, PET and PET/CT in 54/80 pts (68%; CI: 0.56-0.78), 56/80 pts (70%; CI: 0.59-0.80) and 65/80 pts (81%; CI: 0.71-0.89). T3 stage was most difficult to diagnose. T3 tumors were correctly diagnosed with MDCT in 2/11 pts (18%; CI: 0.02-0.52) versus 0/11 pts (0%; CI: 0.00-0.28) with PET and 5/11 pts (45%; CI: 0.17-0.77) with PET/CT. In all imaging modalities, there were no equivocal findings for T4 tumors. Of these, MDCT found the correct tumor stage in 4/6 pts (67%; CI: 0.22-0.95), PET in 3/6 pts (50%; CI: 0.12-0.88) and PET/CT in 5/6 pts (83%; CI: 0.36-0.99). CONCLUSION: Integrated PET/CT was significantly more accurate for T-staging of NSCLC compared to MDCT or PET alone. The advantages of PET/CT are especially pronounced combining T1- and T2-stage as well as in advanced tumors.


Subject(s)
Carcinoma, Non-Small-Cell Lung/diagnostic imaging , Adult , Aged , Carcinoma, Non-Small-Cell Lung/pathology , Female , Fluorodeoxyglucose F18 , Humans , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/pathology , Male , Middle Aged , Neoplasm Staging/methods , Positron-Emission Tomography , Radiopharmaceuticals , Reproducibility of Results , Tomography, X-Ray Computed
6.
J Intern Med ; 260(6): 545-50, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17116005

ABSTRACT

BACKGROUND: Integrated positron emission tomography (PET)/computed tomography (CT) scanners have been recently introduced in the diagnostic work-up of suspected pulmonary malignancy and demonstrate encouraging results in the staging of nonsmall-cell lung cancer. OBJECTIVE: To evaluate the usefulness of integrated FDG PET/CT in pulmonary carcinoid tumours. SETTING: University hospital. METHODS: We studied 13 patients (mean age +/- 1 SD, 57 +/- 11 years) with pulmonary carcinoid tumours. All patients demonstrated a single pulmonary lesion. Integrated PET/CT scan and surgical resection were performed in all patients. RESULTS: The pulmonary lesion size ranged from 1.1 to 5.0 cm. Final histological diagnosis confirmed 12 typical and one atypical pulmonary carcinoid. Mean proliferation rate of the typical carcinoids was 1.7 +/- 1.4%. None of the patients had recurrent carcinoid disease or died during follow-up (864 +/- 218 days). Mean standardized uptake value (SUV) of (18)F-fluorodeoxyglucose (FDG) in typical carcinoids was 3.0 +/- 1.5 (range 1.2 - 6.6); SUV in the atypical carcinoid was remarkably high with a value of 8.5. The SUV was lower than 2.5 in 6 of 12 patients (50%). Mediastinal lymph node metastases or extrathoracic metastases were not detected in any patient. CONCLUSIONS: (18)F-fluorodeoxyglucose PET/CT imaging improves accurate localization of metabolic activity and thus the interpretation of pulmonary lesions on CT. FDG uptake in pulmonary carcinoid tumours is often lower than expected for malignant tumours. Therefore, surgical resection or biopsy of lesions suspected to be carcinoids should be mandatory, even if they show no hypermetabolism on FDG PET images.


Subject(s)
Carcinoid Tumor/diagnosis , Image Enhancement/methods , Lung Neoplasms/diagnosis , Positron-Emission Tomography/methods , Tomography, X-Ray Computed/methods , Adult , Aged , Carcinoid Tumor/diagnostic imaging , Cell Division/physiology , Female , Fluorodeoxyglucose F18/pharmacokinetics , Humans , Lung/diagnostic imaging , Lung Neoplasms/diagnostic imaging , Male , Middle Aged , Radiopharmaceuticals/pharmacokinetics
7.
Urologe A ; 45(10): 1240, 1242-4, 1246-8, 1250, 2006 Oct.
Article in German | MEDLINE | ID: mdl-17006698

ABSTRACT

Of patients with carcinoma of the prostate undergoing therapeutic regimes with curative intent, 15-23% will ultimately relapse and 16-35% will need some sort of salvage therapy within 5 years. Of relapsing patients, 50% will have local recurrence and 50% systemic disease with or without local recurrence. Therefore, localization of recurrent prostate cancer is critical for selecting a local or systemic therapeutic strategy. Modern fusion imaging with PET/CT and 11C/18F-choline or 11C-acetate has augmented the diagnostic imaging spectrum for assessment of relapsing prostate cancer. In 60-70% of patients with biochemical relapse, recurrent tumor can be detected and anatomically precisely localized. Detection sensitivity is probably negatively correlated with serum PSA concentration. Below a PSA level of 1 ng/ml, mean detection sensitivity is probably 50-66%. Fusion imaging with 11C-choline PET/CT and MRI possesses a high potential for early localization of recurrent prostate carcinoma.


Subject(s)
Image Enhancement/methods , Neoplasm Recurrence, Local/diagnosis , Positron-Emission Tomography/methods , Prostatic Neoplasms/diagnosis , Tomography, X-Ray Computed/methods , Humans , Male , Neoplasm Recurrence, Local/prevention & control , Practice Guidelines as Topic , Practice Patterns, Physicians' , Prostatic Neoplasms/therapy , Reproducibility of Results , Sensitivity and Specificity , Subtraction Technique
8.
Urologe A ; 45(6): 707-10, 712-4, 2006 Jun.
Article in German | MEDLINE | ID: mdl-16788788

ABSTRACT

Functional imaging of prostate carcinoma was examined with the metabolic substrates 2-(18)F-fluorodeoxyglucose, (11)C-methionine, (18)F-fluorodihydrotestosterone, (11)C-acetate and (11)C/(18)F-choline. Based on upregulated enzymes of phospholipid metabolism in prostate carcinoma, (11)C/(18)F-choline is preferentially incorporated into phosphatidylcholine of membrane lipids of prostate cancer cells. PET allows sensitive detection of the (11)C/(18)F-choline signal and PET/CT fusion imaging enables intraprostatic signal localisation. Most published studies report a high detection rate of prostate carcinoma with (11)C/(18)F-choline PET/CT. Differentiation of prostate carcinoma from benign hyperplasia and from focal chronic prostatitis may be difficult; acute prostatitis accumulates (11)C/(18)F-choline with an intensity comparable to prostate carcinoma.


Subject(s)
Image Enhancement , Image Processing, Computer-Assisted , Positron-Emission Tomography , Prostatic Neoplasms/diagnosis , Tomography, X-Ray Computed , Carbon Radioisotopes , Diagnosis, Differential , Fluorine Radioisotopes , Humans , Lymphatic Metastasis/pathology , Male , Neoplasm Staging , Prognosis , Prostate/pathology , Prostatic Hyperplasia/diagnosis , Prostatic Hyperplasia/pathology , Prostatic Neoplasms/pathology
9.
Nuklearmedizin ; 45(3): 134-8, 2006.
Article in English | MEDLINE | ID: mdl-16710510

ABSTRACT

AIM: For the therapeutic application of radiopharmaceuticals the activity is determined on an individual basis. Here we investigated the accuracy for a simplified assessment of the residence times for a (188)Re-labelled anti-CD66 monoclonal antibody. PATIENTS, METHODS: For 49 patients with high risk leukaemia (24 men, 25 women, age: 44 +/- 12 years) the residence times were determined for the injected (188)Re-labelled anti-CD66 antibodies (1.3 +/- 0.4 GBq, 5-7 GBq/mg protein, >95% (188)Re bound to the antibody) based on 5 measurements (1.5, 3, 20, 26, and 44 h p.i.) using planar conjugate view gamma camera images (complete method). In a simplified method the residence times were calculated based on a single measurement 3 h p.i. RESULTS: The residence times for kidneys, liver, red bone marrow, spleen and remainder of body for the complete method were 0.4 +/- 0.2 h, 1.9 +/- 0.8 h, 7.8 +/- 2.1 h, 0.6 +/- 0.3 h and 8.6 +/- 2.1 h, respectively. For all organs a linear correlation exists between the residence times of the complete method and the simplified method with the slopes (correlation coefficients R > 0.89) of 0.89, 0.99, 1.23, 1.13 and 1.09 for kidneys, liver, red bone marrow, spleen and remainder of body, respectively. CONCLUSION: The proposed approach allows reliable prediction of biokinetics of (188)Re-labelled anti-CD66 monoclonal antibody biodistribution with a single study. Efficient pretherapeutic estimation of organ absorbed dose may be possible, provided that a more stable anti-CD66 antibody preparation is available.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Antigens, CD/immunology , Cell Adhesion Molecules/immunology , Leukemia/diagnostic imaging , Radioisotopes , Rhenium , Bone Marrow/diagnostic imaging , Humans , Image Processing, Computer-Assisted , Kidney/diagnostic imaging , Liver/diagnostic imaging , Radioisotopes/pharmacokinetics , Radionuclide Imaging , Rhenium/pharmacokinetics , Sensitivity and Specificity , Spleen/diagnostic imaging , Tissue Distribution
10.
Urologe A ; 44(11): 1262, 1264-6, 1268-70, 1272-5, 2005 Nov.
Article in German | MEDLINE | ID: mdl-16247635

ABSTRACT

Prostate cancer is the most common malignancy in males. Men aged 50 years and older are recommended to undergo an annual digital rectal examination (DRE) and determination of prostate-specific antigen (PSA) in serum for early detection. Fortunately, disease-specific mortality continues to decline as a result of advances in screening, staging, and patient awareness. However, about 30% of men with a clinically organ-confined disease show evidence of extracapsular extension or seminal vesicle invasion on pathological analysis. Consequently, there is a need for more accurate diagnostic tools for planning tailored treatment. A variety of modern imaging techniques has been implemented in an attempt to obtain more precise staging, thereby allowing for more detailed counseling, and instituting optimum therapy. This review highlights developments in prostate cancer imaging that may improve staging and treatment planning for prostate cancer patients.


Subject(s)
Biomarkers, Tumor/blood , Diagnostic Imaging/methods , Diagnostic Imaging/trends , Image Interpretation, Computer-Assisted/methods , Prostate-Specific Antigen/blood , Prostatic Neoplasms/diagnosis , Humans , Lymphatic Metastasis , Male , Neoplasm Staging , Practice Guidelines as Topic , Practice Patterns, Physicians'/trends , Technology Assessment, Biomedical
11.
Laryngorhinootologie ; 84(7): 516-9, 2005 Jul.
Article in German | MEDLINE | ID: mdl-16010634

ABSTRACT

A 58 years old male patient presented with a left cervical metastasis of a poorly differentiated squamous cell carcinoma, which was diagnosed by fine needle aspiration cytology. Clinical examination, MRT scans and panendoscopy did not detect the primary tumour site. The positron emission tomography localized an uptake of FDG in the left sided base of the tongue. The patient underwent an ipsilateral modified radical neck dissection and a lateral pharyngotomy. In the left tongue base an induration was palpable which was resected with security distance. The histopathological examination showed a poorly differentiated squamous cell carcinoma with a largest extension of 5 mm x 10 mm.


Subject(s)
Carcinoma, Squamous Cell/diagnostic imaging , Carcinoma, Squamous Cell/secondary , Lymphatic Metastasis/diagnostic imaging , Neoplasms, Unknown Primary/diagnostic imaging , Positron-Emission Tomography , Tongue Neoplasms/diagnostic imaging , Carcinoma, Squamous Cell/pathology , Diagnosis, Differential , Humans , Lymphatic Metastasis/pathology , Male , Middle Aged , Neoplasms, Unknown Primary/pathology , Sensitivity and Specificity , Tongue/diagnostic imaging , Tongue/pathology , Tongue Neoplasms/pathology
12.
Laryngorhinootologie ; 83(6): 391-406; quiz 407-10, 2004 Jun.
Article in German | MEDLINE | ID: mdl-15197680

ABSTRACT

Significance for ENT-tumors. Molecular imaging with PET is based on the use of specific radioactive molecules as source of image contrast. In ENT-tumors mostly glucose and occasionally amino acid/protein metabolism were assessed with PET for tumor diagnosis. Thymidine salvage pathway and proliferation as well as tissue hypoxia are tested already in clinical studies and bear considerable potential for modulation of radiation ports and therapeutic response of cytoreductive regimens. This short review summarises actual clinical indications and potential of PET in ENT-tumors. For both nodal staging as well as detection of recurrent disease, sensitivity and specifity of FDG-PET were 80 - 100 %. FDG-PET proved to be superior to conventional imaging in most published studies. In CUP-syndrome the primary could be detected in 25 - 50 % of patients. Acquisition of PET and CT images in a combined scanner allow versatile PET based metabolic imaging in combination with high resolution and anatomical precise CT-based morphological imaging and thus combines advantages of both imaging modalities. Clinical as well as scientific potential of this functional metabolic and high resolution morphological imaging approach is high.


Subject(s)
Blood Glucose/metabolism , Image Processing, Computer-Assisted , Molecular Probe Techniques , Otorhinolaryngologic Neoplasms/diagnostic imaging , Tomography, Emission-Computed , Tomography, X-Ray Computed , Amino Acids/metabolism , Energy Metabolism/physiology , Fluorodeoxyglucose F18 , Humans , Neoplasm Proteins/metabolism , Neoplasm Staging , Otorhinolaryngologic Neoplasms/pathology , Prognosis , Sensitivity and Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...